following a full submission:
brentuximab vedotin (Adcetris®) is accepted for use within NHSScotland.
Indication under review: in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
In a phase III study, brentuximab vedotin in combination with CHP was associated with a significant improvement in progression-free survival compared with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Medicine details
- Medicine name:
- brentuximab vedotin (Adcetris)
- SMC ID:
- SMC2310
- Indication:
In combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 18 January 2021